LOIS M RAMONDETTA to Treatment Outcome
This is a "connection" page, showing publications LOIS M RAMONDETTA has written about Treatment Outcome.
Connection Strength
0.179
-
A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer. 2011 Apr; 21(3):517-22.
Score: 0.021
-
Surgical removal of a gigantic abdominal mass: a multidisciplinary approach. Obstet Gynecol. 2011 Feb; 117(2 Pt 2):508-512.
Score: 0.021
-
Eleven years: the long and winding road. Gynecol Oncol. 2007 Nov; 107(2):166-8.
Score: 0.017
-
Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. Commun Biol. 2021 02 22; 4(1):237.
Score: 0.011
-
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. 2021 06; 39(3):829-835.
Score: 0.010
-
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020 11; 19(11):2363-2370.
Score: 0.010
-
Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
Score: 0.010
-
The Long-Term Impact of Neurofeedback on Symptom Burden and Interference in Patients With Chronic Chemotherapy-Induced Neuropathy: Analysis of a Randomized Controlled Trial. J Pain Symptom Manage. 2018 05; 55(5):1276-1285.
Score: 0.009
-
Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study. Cancer. 2017 06 01; 123(11):1989-1997.
Score: 0.008
-
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016 12; 5(12):3437-3444.
Score: 0.008
-
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol. 2015 Mar; 16(3):301-11.
Score: 0.007
-
Risk of residual disease and invasive carcinoma in women treated for adenocarcinoma in situ of the cervix. Gynecol Oncol. 2013 Jun; 129(3):513-6.
Score: 0.006
-
A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecol Oncol. 2013 May; 129(2):304-9.
Score: 0.006
-
Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer. Gynecol Oncol. 2010 Dec; 119(3):422-5.
Score: 0.005
-
Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2010 Dec; 119(3):531-7.
Score: 0.005
-
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009 Oct 01; 27(28):4649-55.
Score: 0.005
-
Concurrent chemoradiation in the routine management of patients with cervical cancer: does marital status matter? Int J Gynecol Cancer. 2009 Aug; 19(6):1107-12.
Score: 0.005
-
Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol. 2009 Oct; 115(1):6-11.
Score: 0.005
-
Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment. Int J Radiat Oncol Biol Phys. 2008 Jan 01; 70(1):118-25.
Score: 0.004
-
Active coping mediates the association between religion/spirituality and quality of life in ovarian cancer. Gynecol Oncol. 2006 Apr; 101(1):102-7.
Score: 0.004
-
Malignant mixed M?llerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004 Mar 01; 58(3):786-96.
Score: 0.003